Vivek Ramaswamy's LNP delivery tech play Genevant scores $600M licensing deal from Takeda for nucleic acid therapies

With mRNA vaccines in high demand and new RNA therapeutics crowding onto the market, the demand for lipid nanoparticles has never been higher. Now, one of serial entrepreneur Vivek Ramaswamy’s Vant outfits has scored a big deal with Takeda to develop LNP-delivered liver drugs.